LY3143921 hydrate is a potent and orally bioavailable CDC7 kinase inhibitor. It demonstrates broad-spectrum anticancer activity in vitro and has shown efficacy in preclinical in vivo tumor models, supporting its investigation in cancer research, particularly in DNA replication and cell cycle studies.
